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Secretion and apparent activation of human hepatic lipase requires proper
oligosaccharide processing in the endoplasmic reticulum
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Human hepatic lipase (HL) is a glycoprotein with four N-linked
oligosaccharide side chains. The importance of glycosylation
for the secretion of catalytically active HL was studied in
HepG2 cells by using inhibitors of intracellular trafficking,
N-glycosylation and oligosaccharide processing. Secretion of
HL was inhibited by carbonyl cyanide m-chlorophenylhydra-
zone (CCCP), monensin, brefeldin A (BFA), tunicamycin,
castanospermine and N-methyldeoxynojirimycin, but not by
1-deoxymannojirimycin. Secretion of a
"
-antitrypsin, an unrelated
N-glycoprotein, was also inhibited by monensin, BFA and
tunicamycin, but not by CCCP, castanospermine or N-methyl-
deoxynojirimycin. Intracellular HL activity decreased with
CCCP, tunicamycin, castanospermine and N-methyldeoxynojiri-
mycin, but increased with monensin and BFA. In the absence
of protein synthesis de noo, HL activity secreted into the
medium was 7.8‡2.1-fold higher (mean‡S.D., nfl 7) than the
INTRODUCTION
Hepatic lipase (HL) is an extracellular enzyme that belongs to
the lipase gene superfamily [1]. The enzyme is synthesized and
secreted by liver parenchymal cells, and exerts its function while
bound to the liver in the space of Disse [2,3]. HL hydrolyses
phospholipids and triacylglycerols present in high- and inter-
mediate-density lipoproteins, and facilitates the hepatic uptake
of remnant particles [4–6] and of cholesterol (esters) carried in
high-density lipoproteins [7,8]. In addition, HL might act as a
ligandprotein for remnant binding to the liver [9]. By contributing
to reverse cholesterol transport and by decreasing the number of
atherogenic remnants in the circulation, HL is thought to protect
against the development of premature atherosclerosis. Indeed, a
low HL activity seems to be associated with an increased
atherosclerotic risk [10,11]. In line with this, the aortic accum-
ulation of cholesterol was markedly decreased in cholesterol-
fed transgenic mice that over-expressed human HL [12]. In
human hypertriglyceridaemia, however, post-heparin HL activity
is correlated with the production of highly atherogenic small
dense low-density lipoproteins, suggesting a pro-atherogenic role
for HL in these patients [13].
HL is a glycoprotein bearing two (rat) to four (human)
asparagine-linked glycans [14–16]. For the synthesis and secretion
of fully active HL by rat hepatocytes, N-glycosylation is a
prerequisite [17,18]. This was confirmed by expression studies
with HL cDNA constructs in which the glycosylation sites had
been removed by site-directed mutagenesis [15,16]. These studies
demonstrated that glycosylation at Asn-56}57 of human and rat
HL is both necessary and sufficient for the secretion of cata-
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simultaneous fall in intracellular HL activity. In cells pretreated
with monensin or BFA, this factor decreased to 1.3‡0.5,
indicating that the apparent increase in HL activity had already
occurred within these cells. After chromatography on Sepha-
rose–heparin, the specific triacylglycerol hydrolase activity of
secreted HL was only 1.7‡0.3-fold higher than that of intra-
cellular HL, indicating that the secretion-coupled increase in
HL activity is only partly explained by true activation. We
conclude that oligosaccharide processing by glucosidases in the
endoplasmic reticulum is necessary for the transport of newly
synthesized human HL, but not a
"
-antitrypsin, to the Golgi,
where the catalytic activity of HL is unmasked.
Key words: a
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lytically active lipase [15]. When glycosylation is prevented,
either by tunicamycin or by site-directed mutagenesis, inactive
HL protein accumulates intracellularly [15,19]. When expressed
in Xenopus oocytes, however, a small amount of non-glycosylated
rat HL protein was secreted and catalytically active [20].
This observation argues against the possibility that N-glyco-
sylation itself is necessary for catalytic activity. Rather,
N-glycosylation might be required for the proper intracellular
trafficking of the newly synthesized protein.
Additional studies have shown that for secretion of fully active
rat HL the protein must not only be N-glycosylated but the
glycan chains must subsequently undergo proper processing
[18,21]. The oligosaccharides of N-glycoproteins are generally
processed from high-mannose to complex-type chains success-
ively by glucosidases in the rough endoplasmic reticulum (RER),
mannosidases in the cis- or medial Golgi and glycosyltransferases
in the medial or trans-Golgi [22]. Notably, trimming of the
terminal glucose residues by the RER glucosidases seems to be
crucial for the acquisition of catalytic activity and secretion of rat
HL protein [18,21]. Once the glucose residues have been removed,
activation and subsequent secretion continue independently of
further oligosaccharide processing. Glucose trimming of N-
glycoproteins has been implicated in the quality control system
for newly synthesized proteins, which prevents badly folded
proteins from leaving the RER [23,24]. Whether the presence of
terminal glucose residues itself prevents the acquisition of cata-
lytic activity of rat HL, or whether it primarily interferes with
transport to the Golgi, where subsequently activation can
occur, is unknown.
In the present study we examined the role of N-linked
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glycosylation in secretion and activation of human HL by HepG2
cells. The four putative N-glycosylation sites identified in the HL
cDNA [25] all seem to be occupied in HL secreted by these cells
[15,26]. First, we determined in which intracellular compartment
HL protein is apparently activated, by using inhibitors that
primarily affect vesicular transport in the secretory pathway.
Carbonyl cyanide m-chlorophenylhydrazone (CCCP) and
monensin inhibit the transport of glycoproteins from the RER to
the Golgi [27,28] and from medial to trans-Golgi [22] respectively.
Brefeldin A (BFA) blocks the transport of proteins into post-
Golgi compartments and induces the redistribution of the Golgi
into the RER [29,30]. Secondly, we studied the importance of
oligosaccharide processing in secretion and intracellular acti-
vation of human HL by using inhibitors of glucose trimming in
theRER [castanospermine (CSP) and N-methyldeoxynojirimycin
(MdN)] and mannose trimming in the cis-Golgi [1-deoxym-
annojirimycin (dMM)] [31,32]. The effects of the inhibitors on
the expression of HL were compared with that of a
"
-antitrypsin,
an unrelated N-glycoprotein. The results show that proper
oligosaccharide processing by RER glucosidases is essential for
the secretion of fully active HL but not for the secretion of
a
"
-antitrypsin. Glucose trimming seems to be necessary for the
translocation of HL protein to the Golgi compartment, where
the triacylglycerol hydrolase activity of the protein becomes
detectable.
MATERIALS AND METHODS
Materials
CSP, dMM, (›)-BFA, cycloheximide and CHAPS were from
Boehringer Mannheim (Mannheim, Germany), MdN and endo-
b-N-acetylglucosaminidase H (Endo H) from Genzyme (Boston,
MA, U.S.A.), and monensin and CCCP from Calbiochem (La
Jolla, CA, U.S.A.). Heparin was obtained from Leo Pharma-
ceuticals (Weesp, Holland) ; coupling to CNBr-activated
Sepharose 2B (Pharmacia, Uppsala, Sweden) was performed in
accordance with the manufacturer’s instructions. Trasylol was
from Boehringer Mannheim; other protease inhibitors and
tunicamycin were from Sigma (St. Louis, MO, U.S.A.). Media,
fetal bovine serum and Tran$&S-label (1100 Ci}mmol) were
obtained from ICN (Costa Mesa, CA, U.S.A.). Glycerol
tri[1-"%C]oleate (50–80 mCi}mmol) was from Amersham (Little
Chalfont, Bucks., U.K.). Rabbit antibodies against human a
"
-
antitrypsin and horseradish peroxidase-conjugated rabbit anti-
(goat IgG) were from Dakopatts (Glostrup, Denmark). Zysorbin
was from Zymed Laboratories (San Fransisco, CA, U.S.A.).
Culture plastics and ELISA code 3590 plates were from Costar
(Cambridge, MA, U.S.A.).
HepG2 cell culture and incubation
Human hepatoma HepG2 cells were grown as monolayer cultures
in Dulbecco’s modified Eagle’s medium supplemented with 10%
(v}v) fetal bovine serum [26]. The cells were split 1 :10 into new
flasks once a week. Medium was refreshed once a week. For the
experiments, cells were seeded into six-well plates. At confluence,
the medium was replaced by 1 ml of fresh medium containing
25 i.u.}ml heparin, and the incubations were started with the
addition of inhibitors. CCCP, BFA and monensin were added
from 1000-fold concentrated stock solutions in ethanol ; tuni-
camycin was added from a 1000-fold stock solution in DMSO.
Other inhibitors were added from 100-fold stock solutions in
PBS. The cell cultures were incubated for the indicated durations
at 37 °C in a humidified O
#
}CO
#
(19:1) atmosphere. At the end
of the incubation the plates were placed on ice and all subsequent
handling was done at 4 °C. The medium was collected for
analysis of secreted HL. After being washed twice with PBS, the
cells were released from the plates by a 5 min incubation in PBS
containing 2.5 mM EDTA. Cells were collected by centrifugation
(15 s, 10000 g), and resuspended in 250 ll of a 40 mM NH
%
OH
buffer, pH 8.1 [33], containing 25 i.u.}ml heparin and a cocktail
of protease inhibitors (1 mM EDTA, 10 units}ml Trasylol,
0.1 mM benzamidine, 2 lg}ml leupeptin, 2 lg}ml antipain,
2 lg}ml chymostatin and 2 lg}ml pepstatin). After 30 min on
ice, the lysates were sonicated (15 s, at an amplitude of 14 lm
with an MSE Soniprep 150) and centrifuged for 10 min at
10000 g. The supernatants were used for the analysis of intra-
cellular HL.
HL activity
HL activity was determined by a triacylglycerol hydrolase assay
at pH 8.5 in 0.6 M NaCl with a gum acacia-stabilized glycerol
["%C]trioleate emulsion as substrate [18]. Assays were performed
for 2 h at 30 °C. Activities are expressed as m-units (nmol of free
fatty acids released per min). In a total assay volume of 125 ll,
the release of free fatty acids was linear with time and sample
volume up to 50 ll for the cell-free medium and 20 ll for the cell
lysates. In immuno-inhibition assays, 40 ll of the cell-free
medium or 10 ll of the cell lysates was preincubated for 3 h on
ice in a total volume of 50 ll with 50 lg of goat anti-(human HL)
IgG. This antibody was raised against human HL partly purified
from post-heparin plasma [34]. After centrifugation (10 min,
10000 g, 4 °C), 75 ll of substrate mixture was added to the
supernatant and the residual immunoresistant triacylglycerol
hydrolase activity was determined.
HL mass
The amount of HL protein was determined by solid-phase
ELISA in which the antigen was sandwiched between rabbit and
goat polyclonal antibodies. The rabbit and goat antibodies had
been raised against human HL purified from post-heparin plasma
by the methods of Martin et al. [25] and Persoon et al. [34]
respectively. From the antisera, partly purified IgG fractions
were prepared by 50%-satd. (NH
%
)
#
SO
%
precipitation and elution
through a human albumin–Sepharose column. Polystyrene 96-
well ELISA plates were coated with the rabbit anti-HL IgG.
After blocking with 10 mg}ml BSA in PBS, the wells were
incubated successively with: (1) sample, (2) 3 lg}ml goat anti-
HL IgG in PBS and (3) peroxidase-conjugated rabbit anti-(goat
IgG) at 1:10000 dilution in PBS. Finally, the presence of
peroxidase was detected with 3,3«,5,5«-tetramethylbenzidine
(Merck, Darmstadt, Germany) as substrate. Colour development
was stopped with H
#
SO
%
(4 M final concentration), and A
%&!
was
measured in a Molecular Devices microplate reader. Absorbances
were read against a standard curve prepared for each plate by
serial dilutions of a human post-heparin pool plasma. The HL
activity in this pool plasma amounted to 410 m-units}ml;
HL protein mass was determined as 23.6 lg}ml by reading this
plasma against a standard curve of purified HL. The ELISA
enabled accurate measurements to be made of HL protein in the
range 5–500 ng}ml.
Chromatography on Sepharose–heparin
HepG2 cells were grown in 75 cm# flasks. At confluence the cells
were washed once with medium containing 5 i.u.}ml heparin to
remove any extracellularly bound HL. Subsequently the cells
were incubated for 6–8 h with 7 ml of fresh medium containing
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5 i.u.}ml heparin. Extracellular medium and cell lysates were
then prepared as described above. The medium from four flasks
was pooled (28 ml) and applied to a column of Sepharose–heparin
(0.5 ml wet gel) that had been equilibrated in PBS. Similarly, the
cell lysates from four flasks were pooled (14 ml) and applied to
Sepharose–heparin. After washing the columns with 2 ml of
0.3 M NaCl in 10 mM sodium phosphate (pH 7.0)}1 mg}ml
BSA}10% (v}v) glycerol, bound proteins were eluted with 1.5 ml
of 1.5 M NaCl in the same buffer. The eluates from both columns
were used in immunotitration assays in which approximately
equal amounts of HL activity were incubated with serial dilutions
of the goat anti-(human HL) IgG followed by determination of
the residual triacylglycerol hydrolase activity, as described above.
a1-Antitrypsin
Synthesis and secretion of a
"
-antitrypsin was measured by the
incorporation of [$&S]methionine into immunoprecipitated pro-
tein. HepG2 cells were incubated for 3 h in methionine-free
medium in the presence of inhibitors as described above. Then
80 lCi of Tran$&S-label was added to each well and the incubation
was continued for a further 3 h. Thereafter the plates were put on
ice. The medium was collected into vials containing unlabelled
methionine (final concentration 1 mM) and the cocktail of
protease inhibitors described above. The cells were washed twice
with PBS, then lysed in PBS containing 1% (v}v) Triton X-100,
1% (w}v) sodium deoxycholate, 0.25% SDS, 1 mM meth-
ionine, 25 i.u.}ml heparin, 10 mM Hepes, pH 7.4, and the
cocktail of protease inhibitors. After 30 min on ice, the lysate was
collected from the plate, the sodium deoxycholate concentration
was brought to 0.3% and the lysate was centrifuged for 10 min
at 10000 g. The supernant was used for further analysis.
Samples of medium and cell lysate were incubated with for-
maldehyde-fixed Staphylococcus aureus membranes (Zysorbin)
in the presence of 0.2 mg}ml human serum albumin and centri-
fuged to remove material that bound non-specifically to Protein
A. The supernatants were then incubated with rabbit antibodies
against human a
"
-antitrypsin at a 1:100 dilution. Antigen-
–antibody complexes were precipitated by incubation with
Zysorbin and were collected by centrifugation. Pellets were
washed twice in PBS containing 1% (v}v) Triton X-100, 0.25%
SDS, 0.25% sodium deoxycholate and 1 mM PMSF, then twice
in PBS. The pellets were resuspended in Laemmli’s sample
buffer ; immunoprecipitated proteins were released by being
boiled for 5 min and separated by SDS}PAGE [7.5% (w}v) gel].
The $&S-labelled proteins were detected, and their radioactivity
was determined, by exposure of the dried gels to a phosphor
screen (GS-393 Molecular Imaging System; Bio-Rad, Hercules,
CA, U.S.A.).
In some experiments immunoprecipitated proteins were re-
leased by being boiled for 5 min in 50 mM sodium phosphate
buffer, pH 6.0, containing 0.25% SDS. After removal of the
bacterial membranes (5 min, 10000 g, 4 °C), the eluted proteins
were incubated overnight with 40 m-units}ml Endo H at 37 °C in
50 mM sodium phosphate buffer containing 0.1% SDS [35].
The digestion was stopped by the addition of Laemmli’s sample
buffer, and after being boiled the samples were analysed by
SDS}PAGE and phosphorimaging, as described above. Sen-
sitivity to Endo H was indicated by an increase in electrophoretic
mobility.
Protein synthesis de novo
Incorporation of [$&S]methionine into trichloroacetic acid-pre-
cipitable material was taken as a measure of overall protein
synthesis de noo. HepG2 cells were incubated with Tran$&S-
label, and cell-free medium and cell lysates were prepared as
described above. Aliquots (5 ll) were spotted in duplicate on
Whatman 3MM filters, and precipitation with trichloroacetic
acid was performed as described previously [18]. The radioactivity
on the filters was measured with the Molecular Imaging System.
Statistics
Statistical significances were determined by two-way analysis of
variance (ANOVA) followed by the Student–Newman–Keuls
test.
RESULTS
Synthesis and secretion of HL by HepG2 cells
In the presence of heparin, HepG2 cells secreted lipase activity
into the extracellular medium (Figure 1A), whereas intracellular
activity remained virtually constant throughout the 6–8 h in-
cubation period (Figure 1B). Of the lipase activity present in the
extracellular medium, 67% was sensitive to immuno-inhibition
with anti-(human HL) IgG (0.18‡0.01 compared with
0.06‡0.01 m-unit}ml, means‡S.D., nfl 3, in the absence and
the presence of anti-HL respectively), indicating that the extra-
cellular activity represents mainly HL. Of the activity measured
in the cell lysates, however, approx. 20% was sensitive to
immuno-inhibition (0.13‡0.02 compared with 0.10‡0.01 m-
unit}ml, means‡S.D., nfl 3), suggesting that HL represents
only a small fraction of total intracellular lipase activity. When
cycloheximide was added at the start of the incubation, the
secretion of HL activity was hardly affected during the first 2 h
(Figure 1A), although the inhibition of protein synthesis de noo,
as determined by the incorporation of [$&S]methionine into
trichloroacetic acid-precipitable material, occurred almost in-
stantaneously. Between 3 and 6 h, secretion of HL activity
levelled off and was completely blocked thereafter. Simul-
taneously, intracellular lipase activity decreased (Figure 1B).
After 6–8 h, intracellular lipase activity was no longer sensitive to
immuno-inhibition with anti-HL. These results indicate that,
during the incubation with cycloheximide, pre-existing HL
protein was secreted from the cells.
Comparison of the results in Figures 1(A) and 1(B) shows that,
in the absence of protein synthesis de noo, much more HL
activity appeared in the extracellular medium than simultaneous-
ly disappeared from the cells : whereas 0.45 m-unit was secreted
per well, intracellular activity fell by only 0.05 m-unit per well. In
seven independent experiments, the secretion-coupled increase in
HL activity was 7.8‡2.1-fold (mean‡S.D.). This discrepancy
was not caused by an underestimation of intracellular lipase
activity : first, the triacylglycerol hydrolase assay used was linear
with time and volume of cell lysate (results not shown); secondly,
the triacylglycerol hydrolase activity in medium and cell lysate
were additive when assayed in combination (0.18‡0.01,
0.13‡0.02 and 0.32‡0.02 m-unit}ml, means‡S.D., nfl 3 re-
spectively) ; and thirdly, extraction of lipase activity from the
cells with the NH
%
OH buffer used here was not improved by the
inclusion of a detergent ; the lipase activity was 0.53‡0.04 and
0.47‡0.02 m-unit}ml without and with 8 mM CHAPS in the
lysis buffer respectively (means‡S.D., nfl 6). The amount of
HL protein in the cell lysates was below the detection limit of the
ELISA (see below), so we could not test directly whether HL
protein was extracted efficiently from the cells. We therefore
tested the same extraction conditions on a
"
-antitrypsin, an
unrelated N-glycoprotein. Cells were first pulse-labelled for 1 h
with [$&S]methionine, then chased in the presence of cyclo-
heximide. The amount of $&S-labelled a
"
-antitrypsin that appe-
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Figure 1 Synthesis and secretion of HL activity by HepG2 cells
HepG2 cells were incubated in the presence of 25 i.u./ml heparin without (*) or with (E) 20 lg/ml cycloheximide. At the times indicated, the medium and cells were harvested and triacylglycerol
hydrolase activity was measured in the medium (A) and the cell lysates (B). The results are representative of three similar experiments. Abbreviation : mU, m-unit.
Figure 2 Effect of CCCP on expression of HL and a1-antitrypsin
HepG2 cells were incubated for 6 h in the presence of different concentrations of CCCP. Thereafter the lipase activity (E) and the amounts of HL protein (D) and 35S-labelled a1-antitrypsin
(+) were measured in the extracellular medium (A) and the cell lysates (B). Results are means‡S.E.M. for three independent experiments, except for the amount of HL protein, which was measured
in one experiment. HL activities are expressed as percentages of control (0.66‡0.08 m-unit/ml) ; similarly, radioactivities in a1-antitrypsin (expressed in arbitrary units) are given as percentages
of control. Abbreviation : mU, m-unit.
Table 1 Effect of monensin and BFA on the expression of HL
HepG2 cells were incubated for 6–8 h with or without inhibitors in the presence of heparin. Then cell-free media and cell lysates were prepared for analysis of HL and lipase activity. In parallel
incubations, the effect of the inhibitors on overall protein synthesis was determined by the incorporation of [35S]methionine into trichloroacetic acid-precipitable material. Results are means‡S.E.M.
for three to five independent experiments. *Statistically significant (P ! 0.05) difference from controls.
Addition… None (control) Cycloheximide (20 lg/ml) Monensin (10 lM) BFA (0.2 lg/ml)
Secretion
HL activity (m-unit/ml) 0.92‡0.09 0.37‡0.03* 0.27‡0.02* 0.19‡0.02*
HL protein (ng/ml) 13.1 ! 5 ! 5 ! 5
Intracellular lipase
Activity (m-unit/ml) 1.16‡0.18 0.89‡0.11* 1.54‡0.15* 1.95‡0.12*
HL protein (ng/ml) ! 5 ! 5 6.4 8.8
Overall protein synthesis (% of control) 100 11.2‡3.6* 97.8‡3.8 74.7‡11.3*
ared in the extracellular medium during a 6 h chase with
cycloheximide was 1.6‡0.3-fold higher (mean‡S.D., nfl 3)
than the concomitant decrease in intracellular $&S-labelled a
"
-
antitrypsin. These results indicate that intracellular proteins are
not completely recovered from the cell layers by the protocol
used, but this could not explain the observed 5–10-fold increase
in HL activity associated with secretion. To determine where
along the secretory pathway HL activity is acquired, several
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Figure 3 Apparent activation of HL during secretion in the absence of
protein synthesis de novo
HepG2 cells were preincubated for 6 h with 25 i.u./ml heparin in the absence (Control) or
presence of 0.2 lg/ml BFA or 10 lM monensin (Mon). In each treatment group, two wells
were immediately harvested for measurement of intracellular lipase activity (open bars). Two
other wells were washed free of inhibitor with PBS at room temperature, and incubation was
continued overnight in fresh medium containing heparin and 20 lg/ml cycloheximide to
prevent additional HL synthesis de novo. Thereafter media and cells were harvested. Lipase
activity was determined in the cell lysates (grey bars) and the difference from the activity
measured in the cells before the overnight incubation with cycloheximide was calculated (filled
bars). This difference was compared with the HL activity that was secreted into the extracellular
medium during the overnight incubation with cycloheximide (hatched bars). The results for the
duplicate incubations were averaged. The numbers above the bars indicate the ratio of secreted
activity to the concomitant decrease in intracellular activity. Abbreviation : mU, m-unit.
inhibitors were used that interfere with intracellular vesicle
transport and N-glycosylation.
Effect of inhibitors of intracellular trafficking
With increasing concentrations of CCCP, secretion of HL activity
into the extracellular medium gradually fell to approx. 40% of
control at 5 lM (Figure 2A). The amount of HL protein fell in
parallel. Simultaneously, CCCP decreased the intracellular lipase
activity in a concentration-dependent manner (Figure 2B). With
5 lM CCCP, intracellular lipase activity was similar to that in
cycloheximide-treated cells. Under all conditions, the amount of
Figure 4 Effect of glycosylation inhibitors on the secretion of HL and a1-antitrypsin
HepG2 cells were incubated for 6–8 h in the absence (con) or presence of 20 lg/ml cycloheximide (chx), 10 lg/ml tunicamycin (tun), 100 lg/ml CSP (csp), 1 mM MdN or 1 mM dMM. The
extracellular appearance of HL (A, B) and a1-antitrypsin (C) was measured as outlined in the Materials and methods section. (A) HL activities in the extracellular medium (means‡S.E.M. ;
n fl 6 or 7) are expressed as percentages of control, which was 1.02‡0.10 m-units per well. Except for dMM, the HL activity in the medium containing glycosylation inhibitors was significantly
different (P ! 0.05) from controls. (B) HL activity and amount of HL protein, as determined by ELISA, both measured in the same extracellular medium. (C) a1-Antitrypsin was immunoprecipitated
from medium from 6 h incubations also containing Tran35S-label, and the radiolabelled proteins were analysed by SDS/PAGE and phosphorimaging. Part of the image is shown at the top ; the
molecular mass of the radioactive bands is indicated (in kDa) at the right. The radioactivity in each band (in arbitrary units) is expressed relative to the control incubation. The results in (B) and
(C) are representative of two similar experiments. Abbreviation : mU, m-unit.
intracellular HL protein remained below the detection limit of
the ELISA. In contrast, the secretion of a
"
-antitrypsin was
insensitive to CCCP up to 5 lM. On SDS}PAGE, a
"
-antitrypsin
secreted in the presence of 5 lM CCCP migrated as an Endo H-
resistant 54 kDa band that was indistinguishable from the protein
secreted by control cells (results not shown). The amount of
intracellular a
"
-antitrypsin was not affected by CCCP up to
5 lM (Figure 2B). Intracellular a
"
-antitrypsin consisted of the
Endo H-sensitive 49 kDa and the Endo H-resistant 54 kDa
protein bands also seen in control cells (see Figure 4C).
When HepG2 cells were incubated with 10 lM monensin or
0.2 lg}ml BFA, the secretion of HL activity decreased to levels
well below that observed with cycloheximide (Table 1). The
amount of HL protein in the extracellular medium decreased in
parallel. Simultaneously, the intracellular lipase activity increased
markedly (Table 1). Immuno-inhibition with anti-HL IgG
showed that this increase occurred exclusively in the immuno-
sensitive fraction (results not shown). In addition, the amount of
HL protein was also elevated to levels well above the detection
limit of the ELISA (Table 1). The overall protein synthesis de
noo was not affected by monensin, whereas it was diminished
approx. 25% by BFA. The secretion of newly synthesized a
"
-
antitrypsin was blocked almost completely by monensin and
BFA (results not shown). With both agents, a
"
-antitrypsin
accumulated intracellularly as an Endo H-sensitive 49 kDa
protein.
Apparent activation of HL during incubation with BFA and
monensin
The inhibition of secretion by BFA and monensin and the
concomitant increase in intracellular HL activity was at least
partly reversible. On their removal from the medium, the
secretion of HL activity resumed even in the presence of
cycloheximide. This enabled us to measure the secretion-linked
increase in HL activity in these cells. Cells were first incubated
for 6–8 h with or without BFA or monensin in the presence of
heparin. After removing the extracellular medium, the cells were
re-incubated overnight but in the presence of cycloheximide. As
shown in Figure 3, the intracellular lipase activity of the control
cells decreased by approx. 0.06 m-unit per well, whereas the
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Figure 5 Effect of glycosylation inhibitors on intracellular HL and a1-antitrypsin
Experiments were performed as described in the legend to Figure 4, and lipase activity (A) and radiolabelled a1-antitrypsin (B) were determined in cell lysates. Results for intracellular lipase activity
are means‡S.E.M. (n fl 5 or 6) and are expressed as percentages of control (0.24‡0.05 m-unit per well). Except for dMM, the HL activity in the medium containing glycosylation inhibitors
was significantly different (P ! 0.05) from controls. In (B) the immunoprecipitates prepared from the cell lysates were treated without (fi) or with (›) Endo H before electrophoretic separation ;
the molecular masses of the radioactive proteins are indicated (in kDa) at the left. Results are representative of two similar experiments.
extracellular HL activity increased to 0.50 m-unit per well. This
8.5-fold increase in HL activity is in agreement with the results
presented above. In contrast, the HL activity secreted by BFA-
pretreated cells in the presence of cycloheximide was similar to
the concomitant decrease in intracellular lipase activity. In six
similar experiments the secretion-coupled increase in HL activity
was only 1.3‡0.5-fold (mean‡S.D.) for BFA-treated cells,
whereas a value of 1.9 was found in an experiment with monensin-
treated cells. Hence the apparent activation of HL activity that
is associated with the secretory process has already taken place
in BFA- and monensin-treated cells.
Effect of N-glycosylation inhibitors
After 6–8 h of incubation with tunicamycin, CSP or MdN, the
secretion of HL activity into the medium was inhibited to a
similar extent to that with cycloheximide (Figure 4A). The
secretion of HL protein decreased in parallel with HL activity
(Figure 4B). With tunicamycin, overall protein synthesis de noo
decreased to 86‡17% of control as compared to with 11‡7%
with cycloheximide (means‡S.D., nfl 4). With CSP and MdN,
protein synthesis de noo decreased only slightly to 93‡10%
and 97‡5% of control respectively (means‡S.D., nfl 3). De-
spite normal protein synthesis, the decreased secretion of HL
activity was not accompanied by an increase in intracellular
lipase activity ; instead, intracellular lipase activity decreased to
approx. 75–80% of control cells (Figure 5A). Immuno-inhibition
assays with anti-(human HL) IgG showed that the decrease in
intracellular lipase activity was due to a decrease in the immuno-
sensitive part (results not shown). In contrast with the other
inhibitors, the secretion of both HL activity (Figure 4A) and HL
protein (Figure 4B) continued almost unaffected in the presence
of the mannosidase inhibitor dMM, whereas intracellular lipase
activity was maintained at control levels (Figure 5A). Under all
conditions tested, the amount of HL protein in the cell lysates
remained below the detection limit of the ELISA.
Tunicamycin markedly decreased the secretion of a
"
-anti-
trypsin (Figure 4C); the small amount of a
"
-antitrypsin in the
extracellular medium migrated at an apparent molecular mass of
45 kDa, which corresponds to the non-glycosylated protein. The
secretion of a
"
-antitrypsin was not affected by CSP or MdN. On
SDS}PAGE, the secreted protein was indistinguishable from the
Endo H-resistant 54 kDa protein present in control medium
(Figure 4C). Intracellular a
"
-antitrypsin migrated predominantly
Table 2 Effect of co-incubation of glycosylation inhibitors and BFA on HL
expression
HepG2 cells were incubated for 6–8 h in the presence of heparin with or without BFA
(0.2 lg/ml) and glycosylation inhibitors. At the end of the incubation, cell lysates and cell-free
media were prepared for analysis of triglyceridase activity. Results are means‡S.E.M. for three
to five independent experiments. *Statistically significant (P ! 0.05) difference from the
controls incubated without glycosylation inhibitor.
Intracellular HL Extracellular HL
(m-unit per well) (m-unit per well)
Addition fiBFA ›BFA fiBFA ›BFA
None (control) 0.23‡0.05 0.36‡0.08 1.28‡0.15 0.26‡0.06
Tunicamycin (10 lg/ml) 0.18‡0.07* 0.33‡0.10 0.60‡0.18* 0.26‡0.09
Castanospermine (100 lg/ml) 0.17‡0.06* 0.32‡0.09 0.47‡0.07* 0.20‡0.10
MdN (1 mM) 0.17‡0.06* 0.36‡0.09 0.65‡0.18* 0.22‡0.08
as an Endo H-sensitive 51 kDa band, with the 49 kDa and
54 kDa bands also seen in control cells as minor components
(Figure 5B). Intracellular and extracellular levels of a
"
-antitrypsin
were hardly affected by incubation of the cells with dMM but the
proteins migrated as Endo H-sensitive 49 kDa bands. Hence the
secretion of HL by HepG2 cells was highly sensitive to the RER
glucosidase inhibitors CSP and MdN, whereas that of a
"
-
antitrypsin was not.
Combined effect of BFA and glycosylation inhibitors
When co-incubated with 0.2 lg}ml BFA, CSP (100 lg}ml) and
MdN (1 mM) were no longer able to decrease intracellular
lipase activity in HepG2 cells (Table 2). Instead, intra-
cellular lipase activity increased on incubationwith BFA, whether
or not CSP or MdN was present. By ELISA, similar results were
found for intracellular HL protein (results not shown). The BFA-
induced inhibition of HL secretion (Table 2) and a
"
-antitrypsin
secretion were not affected by co-incubation with the glycosyla-
tion inhibitors. With CSP or MdN, however, the intracellular
appearance of the additional 51 kDa form of a
"
-antitrypsin was
observed in both the absence and the presence of BFA (results
not shown). This observation suggests that the glucosidase
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Table 3 Chromatography on Sepharose–heparin
Secretion media and cell lysates from four 75 cm2 culture flasks were pooled and HL was
isolated by chromatography on a Sepharose–heparin column. The column was washed with
0.3 M NaCl, and bound proteins were eluted with 1 ml of 1.5 M NaCl. Triacylglycerol hydrolase
activity was determined in the elution fractions, and also in the combined breakthrough and
wash fractions, for the calculation of total recovery. The bound fraction of lipase activity was
calculated as a percentage of recovered activity. Results are means‡S.D. for four independent
experiments.
Parameter Medium Cell lysate
Lipase activity applied (m-units) 12.9‡2.8 6.0‡1.5
Total recovery (%) 79.3‡9.5 77.3‡7.5
Bound fraction (%) 62.7‡9.9 34.3‡9.7
Eluted activity (m-units) 6.4‡0.6 1.6‡0.3
Immunosensitive fraction (%) 84.5‡7.5 72.0‡8.8
Figure 6 Immunotitration of secreted and intracellular HL after isolation
on Sepharose–heparin
HL from secretion medium (D) and cell lysate (E) was bound to Sepharose–heparin. After
the column had been washed with 0.3 M NaCl, bound proteins were eluted in a single batch
with 1.5 M NaCl. The activity of secreted HL was diluted with elution buffer to the same activity
as in the intracellular HL fraction (approx. 1.2 m-units/ml). Both preparations were incubated
with goat anti-(human HL) IgG at different dilutions, and the residual triacylglycerol hydrolase
activity was measured. Results (means‡S.D., n fl 4) are expressed as percentages of the
activity measured after parallel incubations in the absence of anti-HL. Abbreviation : un,
undiluted.
inhibitors were still effective in the presence of BFA. Nevertheless
their inhibitory effect on intracellular HL activity was overcome
by co-incubation with BFA.
Immunotitration of intracellular and secreted HL
In a large-scale experiment, HL was isolated from 6–8 h medium
and cell lysates by binding to Sepharose–heparin followed by
batchwise elution with 1.5 M NaCl. For both sources, total
recovery of lipase activity was approx. 80%, but only 35% of the
lipase activity in the cell lysate bound to the column compared
with 65% of the activity from medium (Table 3). In contrast
with the cell lysate, the lipase activity in the single elution
fraction was largely sensitive to immuno-inhibition with anti-
(human HL) IgG, as with the medium fraction. After adjusting
the medium fraction with elution buffer to the same HL activity
as the lysate fraction, both fractions were subjected to immuno-
inhibition with serially diluted anti-(human HL) IgG (Figure 6).
Between 300-fold and 3-fold dilution of the antibody preparation,
the HL activity decreased gradually in both fractions. In four
independent experiments, we found a small but significant
difference (Pfl 0.04) between the two immunotitration curves.
Compared with the curve for intracellular HL, that for secreted
HL was shifted towards higher antibody dilutions and thus
towards lower antibody titres. This suggests that after chro-
matography on Sepharose–heparin, the specific enzyme activity
of secreted HL was 1.7‡0.3-fold higher (mean‡S.D., nfl 4)
than that of intracellular HL. Using the same approach, we did
not detect inactive HL in the column breakthrough plus wash
fractions (results not shown).
DISCUSSION
We show here that HL activity increases 5–10-fold during
maturation in human HepG2 cells. After chromatography on
Sepharose–heparin, the specific enzyme activity of secreted HL
was less than 2-fold greater than that of intracellular HL, which
suggests that the increase in enzyme activity is only partly
explained by true activation. Apparently the previously hidden
enzyme activity of HL protein becomes unmasked during matu-
ration. Several lines of evidence suggest that this increase in
enzyme activity occurs in the cis- to medial Golgi region of the
secretory pathway. First, this apparent activation has already
occurred in cells treated with monensin, which inhibits intra-
Golgi transport (Figure 3). Secondly, when HL protein is retained
within the RER, by treating the cells either with CCCP (Figure
2) or with the glucosidase inhibitors CSP or MdN (Figure 5),
intracellular HL activity does not increase. Thirdly, when the
contents of the Golgi stacks are transported back into the RER
by treating the cells with BFA, the effect of CSP and MdN on
intracellular HL activity is reversed (Table 2). The mechanism by
which the catalytic activity of HL is unmasked in the cis- to
medial Golgi remains unknown. It is unlikely that the trimming
of mannose residues by Golgi mannosidase I itself is responsible
for the apparent activation, because inhibition of this process in
situ by dMM has no effect on the intrcellular and secreted HL
activity (compare Figures 4 and 5).
Previous studies with Chinese hamster ovary cells transfected
with HL cDNA constructs have demonstrated that N-linked
glycosylation of rat and human HL is essential for the secretion
of a catalytically active protein by these cells [15,16]. N-gly-
cosylation of human HL was shown to be necessary for the
proper intracellular trafficking of newly synthesized protein
[15,20]. Here we show that the secretion of catalytically active
human HL by HepG2 cells requires not only N-glycosylation but
also subsequent glucose trimming by RER glucosidases I and II.
In this respect human HL behaves similarly to rat HL, the
secretion and apparent activation of which are also highly
sensitive to inhibition by RER glucosidase inhibitors [18,21], but
differently from a number of other N-glycoproteins including
a
"
-antitrypsin (Figure 4) [35,36]. Glucose trimming by the RER
glucosidases has been implicated in the quality control system of
the secretory pathway, which prevents badly folded or un-
assembled glycoproteins from leaving the RER for the Golgi
[23,24]. In this model, glycoproteins bearing terminal glucose
residues associate with the molecular chaperone calnexin, which
assists in the folding process [23,37,38]. Our observations suggest
that glucose trimming of newly synthesized HL protein is
necessary for folding into a transport-competent form. In the
presence of the glucosidase inhibitors CSP and MdN, or in the
absence of N-glycosylation, only a small amount of newly
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synthesized HL, if any, is properly folded and subsequently
transported to the Golgi and beyond.
Why HL trafficking depends so much more on glucose
trimming than a
"
-antitrypsin remains unclear. Unlike that of
HL, the secretion of a
"
-antitrypsin was unaffected by CSP or
MdN. In the presence of these inhibitors, the maturation of a
"
-
antitrypsin proceeded through a distinct intracellular intermedi-
ate of 51 kDa (Figure 5C) [35]. Despite the inhibition of the RER
glucosidases, a
"
-antitrypsin seemed to be normally deglucosyl-
ated and further processed to the Endo H-resistant form. The
Golgi system of HepG2 cells is shown to contain a endo-a-d-
mannosidase that removes the mannose residue with the attached
glucoses, thereby providing an alternative processing route for
a
"
-antitrypsin and several other N-glycoproteins [36,39]. Utiliz-
ation of this alternate route requires that these glycoproteins are
first transported from the RER to the Golgi. Apparently the
Golgi endo-mannosidase is not accessible to HL protein in CSP-
and MdN-treated HepG2 cells, probably because the presence
of the terminal glucose residues prevents HL protein, but not a
"
-
antitrypsin, from leaving the RER. Compared with that of
a
"
-antitrypsin, the maturation of HL was also much more
sensitive to inhibition by CCCP (Figure 2), an H+-ionophore and
mitochondrial uncoupler. This observation might indicate that
the folding of HL into a transport-competent structure requires
some additional pH- or ATP-dependent steps such as the release
from chaperones in the RER. Perhaps a
"
-antitrypsin folds into a
transport-competent form without the help of such ATP-de-
pendent chaperones. Alternatively, as human HL and rat HL
seem to be oligomeric proteins [40–43], the proper folding of
HL might require assembly into oligomers, in contrast with the
monomeric a
"
-antitrypsin.
The effects of the glucosidase and trafficking inhibitors reported
here are best explained by a model in which glucose trimming of
HL in the RER is necessary for transport to the Golgi, where its
triacylglycerol hydrolase activity becomes detectable. Glucose
trimming in the RER is necessary for newly synthesized and
properly folded HL protein to detach from calnexin. Other RER
chaperones can then bind to HL, which prevents activation or
masks its catalytic activity. These chaperones can escort HL to
the Golgi compartment, where HL is liberated and its catalytic
activity becomes apparent.
These studies were supported by the Dutch Heart Foundation (grant no. 91.075).
REFERENCES
1 Hide, W. A., Chan, L. and Li, W.-H. (1992) J. Lipid Res. 33, 167–177
2 Jackson, R. L. (1983) in The Enzymes, vol. 16 (Boyer, P. D., ed), pp. 141–180,
Academic Press, New York
3 Breedveld, B., Schoonderwoerd, K., Verhoeven, A. J. M., Willemsen, R. and
Jansen, H. (1997) Biochem. J. 321, 425–430
4 Sultan, F., Lagrange, D., Jansen, H. and Griglio, S. (1990) Biochim. Biophys. Acta
1042, 150–152
5 Chang, S. and Borensztajn, J. (1993) Biochem. J. 293, 745–750
6 Ji, Z. S., Lauer, S. J., Fazio, S., Bensadoun, A., Taylor, J. M. and Mahley, R. W.
(1994) J. Biol. Chem. 269, 13429–13436
Received 10 August 1998 ; accepted 21 October 1998
7 Bamberger, M., Glick, J. M. and Rothblat, G. H. (1983) J. Lipid Res. 24, 869–876
8 Marques-Vidal, P., Aze!ma, C., Collet, X., Vieu, C., Chap, H. and Perret, B. (1994)
J. Lipid Res. 35, 373–384
9 Krapp, A., Ahle, S., Kersting, S., Hua, Y., Kneser, K., Nielsen, M., Gliemann, J. and
Beisiegel, U. (1996) J. Lipid Res. 37, 926–936
10 Barth, J. D., Jansen, H., Kromhout, D. J. H. C., Birkenha$ ger, J. C. and Arntzenius,
A. C. (1987) Atherosclerosis 68, 51–58
11 Groot, P. H. E., van Stiphout, W. A. H. J., Krauss, X. H., Jansen, H., van Tol, A., van
Ramshorst, E., Chin-On, S., Hofman, A., Cresswell, S. R. and Havekes, L. (1991)
Arterioscl. Thromb. 11, 653–662
12 Busch, S. J., Barnhart, R. L., Martin, G. A., Fitzgerald, M. C., Yates, M. T., Mao,
S. J. T., Thomas, C. E. and Jackson, R. L. (1994) J. Biol. Chem. 269, 16376–16382
13 Zambon, A., Austin, M. A., Brown, B. G., Hokanson, J. E. and Brunzell, J. D. (1993)
Arterioscler. Thromb. 13, 147–153
14 Doolittle, M. H., Wong, H., Davis, R. C. and Schotz, M. C. (1987) J. Lipid Res. 28,
1326–1333
15 Wo$ lle, J., Jansen, H., Smith, L. C. and Chan, L. (1993) J. Lipid Res. 34, 2169–2176
16 Ben-Zeev, O., Stahnke, G., Liu, G., Davis, R. C. and Doolittle, M. H. (1994) J. Lipid
Res. 35, 1511–1523
17 Leitersdorf, E., Stein, O. and Stein, Y. (1984) Biochim. Biophys. Acta 794, 261–268
18 Verhoeven, A. J. M. and Jansen, H. (1990) J. Lipid Res. 31, 1883–1893
19 Laposata, E. A., Laboda, H. M., Glick, J. M. and Strauss, III, J. F. (1987) J. Biol.
Chem. 262, 5333–5338
20 Stahnke, G., Davis, R. C., Doolittle, M. H., Wong, H., Schotz, M. C. and Will, H.
(1991) J. Lipid Res. 32, 477–484
21 Verhoeven, A. J. M. and Jansen, H. (1991) Biochim. Biophys. Acta 1086, 49–56
22 Elbein, A. D. (1987) Annu. Rev. Biochem. 56, 497–534
23 Hammond, C., Braakman, I. and Helenius, A. (1994) Proc. Natl. Acad. Sci. U.S.A. 91,
913–917
24 Helenius, A. (1994) Mol. Biol. Cell 5, 253–265
25 Martin, G. A., Busch, S. J., Meredith, G. D., Cardin, A. D., Blankenship, D. T., Mao,
S. J. T., Rechtin, A. E., Woods, C. W., Racke, M. M., Schafer, M. P. et al. (1988)
J. Biol. Chem. 263, 10907–10914
26 Busch, S. J., Martin, G. A., Barnhart, P. L. and Jackson, R. L. (1989) J. Biol. Chem.
264, 9527–9532
27 Burkhardt, J. K. and Argon, Y. (1989) J. Cell Sci. 92, 633–642
28 Doms, R. W. (1990) Methods Enzymol. 191, 841–854
29 Fujiwara, T., Oda, K., Yokota, S., Takatsuki, A. and Ikehara, Y. (1988) J. Biol. Chem.
263, 18545–18552
30 Lippincott-Schwartz, J., Yuan, L. C., Bonifacino, J. S. and Klausner, R. D. (1989) Cell
56, 801–803
31 Fu$ hrmann, U., Bause, E. and Ploegh, H. (1985) Biochim. Biophys. Acta 825, 95–110
32 McDowell, W. and Schwarz, R. T. (1988) Biochimie 70, 1535–1549
33 Kihara, S., Wo$ lle, J., Ehnholm, C., Chan, L. and Oka, K. (1993) J. Lipid Res. 34,
961–970
34 Persoon, N. L. M., Sips, H. J. and Jansen, H. (1986) Life Sci. 38, 1029–1033
35 Kuznetsov, G., Brostrom, M. A. and Brostrom, C. A. (1993) J. Biol. Chem. 268,
2001–2008
36 Rabouille, C. and Spiro, R. G. (1992) J. Biol. Chem. 267, 11573–11578
37 Ou, W.-J., Cameron, P. H., Thomas, D. Y. and Bergeron, J. J. M. (1993) Nature
(London) 364, 771–776
38 Hebert, D. N., Foellmer, B. and Helenius, A. (1995) Cell 81, 425–433
39 Moore, S. E. H. and Spiro, R. G. (1990) J. Biol. Chem. 265, 13104–13112
40 Ehnholm, C., Greten, H. and Brown, W. V. (1974) Biochim. Biophys. Acta 360,
68–77
41 Jensen, G. L. and Bensadoun, A. (1981) Anal. Biochem. 113, 246–252
42 Hill, J. S., Davis, R. C., Yang, D., Wen, J., Philo, J. S., Poon, P. H., Phillips, M. L.,
Kempner, E. S. and Wong, H. (1996) J. Biol. Chem. 271, 22931–22936
43 Berryman, D. E., Mulero, J. J., Hughes, L. B., Brasaemle, D. L. and Bensadoun, A.
(1998) Biochim. Biophys. Acta 1382, 217–229
